Value
4.2/10data confidence 67%| Component | Sub-score |
|---|---|
| P/E | 6.6 |
| P/S | 3.8 |
| Fwd P/E | 1.0 |
| Analyst target | 6.0 |
- ▸Forward P/E: 89.3x
CAI · Why this verdict
Why Caris Life Sciences (CAI) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Caris Life Sciences is a high-growth biotech with strong quality scores, but a forward P/E of 92x, heavy insider selling and a price above the analyst target make it expensive ahead of earnings.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue is growing 45% YoY, the Piotroski score is 9/9, and a Rule of 40 reading of 52 passes. Growth breakdown | Growth stays above 30% YoY over 12 months. | →Stable |
| CounterGrowth this high is hard to sustain and 84.4% of revenue comes from one product. | ||
Forward P/E is 92.3x, and forward earnings are 4.5 times the trailing level, a rich price. Valuation breakdown | Earnings catch up and forward P/E drops below 60x. | ↑Improving |
| CounterA stock priced for perfection can fall sharply on any growth miss. | ||
Insiders sold about $27.2M (0.28% of market cap) and institutions are reducing. Insider breakdown | Insider selling slows below 0.1% of market cap. | →Stable |
| CounterSelling may be post-IPO lockup diversification, which tells little about fundamentals. | ||
MI Profile tissue-based profiling is 84.4% of revenue and sequencers come from sole suppliers. Bear case | New products lower the MI Profile share below 80%. | ↓Deteriorating |
| CounterThe concentrated product is the growth engine; diversification could dilute margins. | ||
Revenue is growing 45% YoY, the Piotroski score is 9/9, and a Rule of 40 reading of 52 passes.
→StableGrowth breakdown
- Expectation
- Growth stays above 30% YoY over 12 months.
CounterGrowth this high is hard to sustain and 84.4% of revenue comes from one product.
Forward P/E is 92.3x, and forward earnings are 4.5 times the trailing level, a rich price.
↑ImprovingValuation breakdown
- Expectation
- Earnings catch up and forward P/E drops below 60x.
CounterA stock priced for perfection can fall sharply on any growth miss.
Insiders sold about $27.2M (0.28% of market cap) and institutions are reducing.
→StableInsider breakdown
- Expectation
- Insider selling slows below 0.1% of market cap.
CounterSelling may be post-IPO lockup diversification, which tells little about fundamentals.
MI Profile tissue-based profiling is 84.4% of revenue and sequencers come from sole suppliers.
↓DeterioratingBear case
- Expectation
- New products lower the MI Profile share below 80%.
CounterThe concentrated product is the growth engine; diversification could dilute margins.
Per-dimension breakdown
Quality
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 6.7 |
| ROA | 5.8 |
| Gross margin | 10.0 |
| Op margin | 4.1 |
| Net margin | 5.3 |
| Current ratio | 7.5 |
| FCF quality | 4.7 |
| Moat | 8.2 |
| Rule of 40 | 8.5 |
| Piotroski F | 10.0 |
- ▸Earnings quality warning: 60% FCF/NI
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
- ▸Rule of 40: 52 (pass)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 45% YoY
Momentum
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 7.5 |
| MACD | 0.0 |
| OBV | 5.4 |
| MA position | 4.0 |
| Volume | 3.7 |
- ▸Uptrend pullback (RSI 40) - buy opportunity
- ▸Above 200-day MA
Sentiment
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 3.8 |
| Analyst rating | 7.2 |
| Price target | 7.8 |
- ▸Analyst upside: 21%
Insider
2.0/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 0.0 |
| notable moves | 3.0 |
- ▸Notable insider selling — $27,204,813 (0.290% of mkt cap)
- ▸Institutions reducing
Peer rank
5.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.2 |
| quality rank | 7.5 |
| growth rank | 6.9 |
- ▸Superior ROE vs peers
Technical
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 10.0 |
| support resistance | 9.0 |
| 52w position | 4.7 |
| gap | 7.5 |
- ▸Extreme gap down (-18.2%) - potential reversal
Risk (lower is worse)
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.1 |
| days to cover | 8.2 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| debt equity | 6.4 |
- ▸Elevated put/call: 3.43
- ▸High IV: 96%
- ▸Above max pain $15
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
How the verdict was assembled
Engine trigger
Heavy insider selling.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:INSIDER_FLOORPassed (4)
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:4.1<4.5
- ASYMMETRY:0.4<1.5@spot
Warning (2)
- INSIDER:0.29%=MODERATE
- 8K_FLAG:1.02
Reward-to-Risk
0.37
Upside
+5.5%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 4.1<4.5 outcome against Growth at 10.0 and asymmetric R:R of 0.37.
The strongest dimensions are Growth at 10.0, Catalyst at 8.2, and Technical at 7.8; the weakest are Insider at 2.0, Risk (lower is worse) at 3.1, and Momentum at 4.1. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of 0.37 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Growth Quality
Trip ifRevenue growth falls below 30% YoY.
- P2Stretched Valuation
Trip ifForward P/E stays above 80x for 2 consecutive quarters.
- P3Insider Selling Pressure
Trip ifInsider selling exceeds 0.5% of market cap in a 90-day window.
- P4Product Concentration Risk
Trip ifMI Profile share of revenue stays above 85%.